- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04821544
Estrés materno sobre la leche materna y los resultados del lactante
Efectos del estrés materno sobre la composición de la leche humana y los resultados posteriores del lactante
The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) or 8 weeks of 2000 IU vitamin D supplementation will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
During every two-week period, newly admitted infants (both preterm <37 weeks gestational age and term ≥37 weeks gestational age) at performance site Kootenai Health NICU and term infants from the Palouse region will be block randomized to control (standard of care), mindfulness intervention (modified 8-week mindfulness
-based intervention (with a focus on self-compassion; MBSC), or vitamin D supplementation (8-week 2,000 IU vitamin D3 supplementation) groups. The purpose of the nested cohorts is to minimize the postpartum time difference among cohort mothers. Each nested MBSC cohort will undergo the 8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
Maternal data: The Perceived Stress Scale (PSS) and Self-Compassion Scale-Short Form (SCS-SF) will be given to mothers from both groups pre- and post-intervention, and during the 4th week. Saliva, urine, stool, and human milk samples will be collected at the same time points as above. Additional maternal data include: age, race, height, weight (pre-pregnancy and last weight before delivery), parity, delivery mode, chorioamnionitis, preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome, antenatal antibiotics, anti-depressants or other mood-altering/neurochemical medications (current and during pregnancy), diagnosis of depression or other mental illness within the previous 5 years, history of postpartum depression and postpartum psychosis, diabetes, hypertension, heart disease, and any inflammatory or autoimmune diseases.
Infant data: Gestational age, birth weight, ventilation requirement, surgical interventions, patent ductus arteriosus, growth, nutrition prescriptions, saliva, urine and stool samples.
Data collection: All data (not including biosamples) will be collected using REDCap hosted within the UI system.
Sample measurements: Maternal salivary cortisol (marker of stress) and oxytocin (marker of anxiety and "social-closeness") concentrations will be measured using ELISA. Human milk proteins will be identified using mass spectrometry-based proteomics. Following proteomic analyses, targeted proteins will be quantified using ELISA and Western Blot. Both maternal and infant saliva, urine and stool samples will be used for metabolomic and transcriptomic sequencing to identify metabolic and molecular changes, respectively, in both mothers and infants. Infant systemic oxidative stress will be measured through urine F2-isoprostanes concentrations (ELISA), and infant intestinal inflammation will be determined with stool calprotectin concentrations (ELISA).
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Yimin Chen, PhD
- Número de teléfono: 2088857264
- Correo electrónico: yiminc@uidaho.edu
Ubicaciones de estudio
-
-
Idaho
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Reclutamiento
- Kootenai Health
-
Contacto:
- Brook Lang, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Mothers of newborn infants at Kootenai Health NICU and the Palouse region
Exclusion Criteria:
-
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Control
Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period. This group will also receive placebo gummies that appear the same as the vitamin D gummies. |
|
|
Experimental: Mindfulness-based intervention (with a focus on self-compassion; MBSC)
8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator. |
8-week MBSC intervention with a focus on increasing self-compassion |
|
Experimental: Vitamin D
Vitamin D gummies of 2,000 IU/day for 8 weeks. |
Vitamin D at 2,000 IU/day for 8 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maternal Stress - Biomarker Change
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Salivary cortisol - Change from Baseline cortisol to 4 and 8 weeks |
Baseline to 4 and 8 weeks
|
|
Maternal Stress - Psychometric Measure Change
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Perceived Stress Scale (PSS) - Change from Baseline PSS to 4 and 8 weeks The Perceived Stress Scale (PSS) is validated and the most widely used instrument to measure perception of stress. The PSS includes 14 questions inquiring about feelings and thoughts during the past month expressed through frequency. The PSS will be used pre-intervention, post-intervention (8 weeks), and at the mid-point of the intervention (4 weeks). The scale for each question ranges from 0-4. The PSS measures how often the responder found life to be unpredictable, uncontrollable, and overloaded. Higher score indicates higher perceived stress. The total score ranges between 0-56. |
Baseline to 4 and 8 weeks
|
|
Maternal Self-compassion - Biomarker Change
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Salivary oxytocin - Change from Baseline oxytocin to 4 and 8 weeks |
Baseline to 4 and 8 weeks
|
|
Maternal Self-compassion - Psychometric Measure Change
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Self-Compassion Scale-Short Form (SCS-SF) - Change from Baseline SCS-SF to 4 and 8 weeks The Self-Compassion Scale-Short Form (SCS-SF)19 is a shortened and highly correlated (r ≥ 0.97) scale (12 items) from the original 26-item SCS. The SCS-SF measures six key components of self-compassion using a scale that ranges from 1-5: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Self-compassion is associated with psychological well-being and is therefore often measured alongside stress and anxiety. High score indicates higher self-compassion. The total score ranges between 0-60. |
Baseline to 4 and 8 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Human Milk Proteins & Peptides Change
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Protein and peptide profiles will be measured using proteomic & peptidomic analyses to assess human milk protein and peptide changes from baseline to 4 and 8 weeks as a function of maternal changes in stress/self-compassion. These are measured outcomes. |
Baseline to 4 and 8 weeks
|
|
Maternal Metabolomic & Transcriptomic Changes
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Maternal metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to changes in stress/self-compassion. These are measured outcomes. |
Baseline to 4 and 8 weeks
|
|
Infant Metabolomic & Transcriptomic Changes
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Infant metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to maternal changes in stress/self-compassion, and human milk protein/peptide profile changes. These are measured outcomes. |
Baseline to 4 and 8 weeks
|
|
Maternal Vitamin D Changes
Periodo de tiempo: Baseline to 4 and 8 weeks
|
Maternal vitamin D status changes in both serum and human milk from baseline to 4 and 8 weeks. |
Baseline to 4 and 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Yimin Chen, PhD, University of Idaho
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Desordenes mentales
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Complicaciones obstétricas del parto
- Complicaciones del embarazo
- Trastornos del estado de ánimo
- Trastornos Puerperales
- Desorden depresivo
- Depresión, Posparto
- Trabajo de parto prematuro, obstétrico
- Compuestos policíclicos
- Esteroides
- Compuestos de anillo fusionado
- Subesteroides
- Vitamina d
Otros números de identificación del estudio
- 20-024
- 5U54GM104944-08 (Subvención/contrato del NIH de EE. UU.)
- P20GM152304 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
IPD will be available upon request.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .